Emma Beatrice Croce

Dr. Emma Beatrice Croce


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2025 in Genes
Verified
Journal Article
Open access
PDF file
Simone GrassiSimone Grassi
Simone Grassi
ACAndrea Costantino
Andrea Costantino
ADAlexandra Dimitrova
Alexandra Dimitrova
ECEmma Beatrice Croce
Emma Beatrice Croce
FIFrancesca Iasi
Francesca Iasi
FVFabio Vaiano
Fabio Vaiano
Background/Objectives: Epigenetics refers to heritable modifications in gene expression that do not involve changes to the DNA sequence. Among these, DNA methylation, histone modifications, and non-coding RNAs play a key role in regulating gene activity and are influenced by environmental factors, including exposure to psychoactive substances. In recent years, it has been hypothesized that such alterations may serve as molecular markers with forensic relevance. This systematic review aims to evaluate whether current evidence supports the use of drug-induced epigenetic changes as potential toxicological fingerprints in human subjects. Methods: A systematic literature search was conducted following PRISMA guidelines, including articles published on PubMed between 1 January, 2010, and 31 December, 2025. Only studies conducted on human samples and published in English were considered; animal studies and articles lacking epigenetic data were excluded. Results: Forty-two studies met the inclusion criteria. The most commonly investigated substances (alcohol, cocaine, methamphetamine, cannabis, and opioids) were found to induce specific and, in some cases, persistent epigenetic changes. These include alterations in CpG methylation in promoter regions, variations in miRNA expression, and modulation of epigenetic enzymes. Such changes were observed in brain tissue, blood cells, and semen, with evidence of persistence even after drug cessation. Conclusions: Current evidence confirms that psychoactive substance use is associated with specific epigenetic modifications. However, forensic application remains limited due to confounding factors such as age, co-exposures, and post-mortem interval. Further standardized research is necessary to validate their use as forensic biomarkers.

10 October 2024 in Forensic Sciences
Verified
Journal Article
Open access
PDF file
ADAlexandra Dimitrova
Alexandra Dimitrova
ECEmma Beatrice Croce
Emma Beatrice Croce
GIGaia Iaquinta
Gaia Iaquinta
EFElisa Ferri
Elisa Ferri
SFSimone Faccioli
Simone Faccioli
FVFabio Vaiano
Fabio Vaiano
The use of cerebrospinal fluid (CSF) in post-mortem (PM) toxicological analysis is an under-addressed topic, likely due to the technical complexity of the collection of a proper sample. However, it is a matrix of significant interest since it has similar chemical and physical properties to the blood and it is less exposed to risks like PM redistribution and diffusion due to its anatomical location. This study aimed to validate a sensitive analytical method for the quantification of drugs of abuse and their metabolites (i.e., cocaine, ketamine, amphetamine, MDPV, 6-monoacetylmorphine, morphine, codeine, and methadone) through liquid chromatography–tandem mass spectrometry (LC-MS/MS). CSF was collected through ventricular puncture, and 200 µL was deproteinated with acetonitrile (600 µL). Quantification was carried out, acquiring two MRM transitions for each compound in positive ionization mode. Chromatographic separation was achieved with a C18 column. Limits of quantification ranged from 0.05 to 5 ng/mL. Bias and precision were always within the acceptance criteria. Ion enhancement and suppression effects were observed depending on the substance. The method validated here was applied to a real case, proving to be suitable for PM analysis. CSF and blood were positive for methadone (460 vs. 280 ng/mL), cocaine (125 vs. 69 ng/mL), benzoylecgonine (4640 vs. 3160 ng/mL), and lorazepam (19 vs. 25 ng/mL). In the future, this will be useful for the evaluation of CSF as a valuable alternative matrix in PM investigations.

28 July 2026 in Sci
Verified
Journal Article
Open access
PDF file
Sara SabloneSara Sablone
Sara Sablone
ACAndrea Costantino
Andrea Costantino
FLFederica Laurenzano
Federica Laurenzano
GFGiulia Ferretti
Giulia Ferretti
ECEmma Beatrice Croce
Emma Beatrice Croce
Simone GrassiSimone Grassi
Simone Grassi
The digitalization of healthcare systems has transformed the production, storage, and sharing of clinical information. While electronic health records (EHRs) enhance care efficiency, accessibility, and continuity, they simultaneously introduce complex ethical, legal, and cybersecurity challenges that directly affect patient interests. This narrative review examines the emerging rights associated with digital health records, particularly the right to privacy and the right to be forgotten, alongside threats to confidentiality, cybersecurity, and patient safety. A comprehensive literature search was conducted across PubMed, Web of Science, MEDLINE, and the Cochrane Library. First, the right to be forgotten appears particularly relevant for oncological patients facing financial discrimination and for individuals asserting gender identity rights, yet it cannot be unconditionally extended to genetic data, given its relevance to relatives and future generations. Second, confidentiality risks are amplified by re-identification vulnerabilities, unauthorized access by personnel, and the broad connectivity of digital systems. Third, the secondary use of data from EHRs, including artificial intelligence (AI) integration, commercial exploitation, and large language model training, raises substantial privacy concerns. Fourth, ransomware, phishing, and data breaches can erode patient trust. In this article, we analyze these issues within the evolving European regulatory framework, highlighting the tension between individual privacy rights and broader public interests. We argue that robust data protection must be balanced with scientific progress and that this requires opt-in consent frameworks, staff training, and transparent AI governance.